SUMMARY
S. Vincent Rajkumar, M.D., is engaged in clinical, epidemiological and laboratory research in myeloma and related disorders. Dr. Rajkumar served as the principal investigator on several clinical trials for the treatment of myeloma, including the pivotal trials that led to the regulatory approval of thalidomide for the treatment of the disease in the United States.
Focus areas
- Biomarkers for diagnosis of multiple myeloma and related disorders
- Novel therapies for multiple myeloma
- Epidemiology and prognosis of myeloma and related monoclonal gammopathies
- Clinical trials for myeloma and related disorders
- Racial disparities in myeloma and related plasma cell disorders
Significance to patient care
The research being conducted by Dr. Rajkumar will lead to better treatments and outcomes for patients with myeloma and other hematologic malignancies.
Professional highlights
- Waldenstrom Award for Outstanding Researchers, International Myeloma Society, 2021
- Distinguished Investigator Award, Mayo Clinic, 2018
- Editor-in-chief, Blood Cancer Journal, 2014-present
- Associate Editor, European Journal of Haematology, 2012-present
- Member, Myeloma Steering Committee, National Cancer Institute, 2010-present
- Member of the board of directors, International Myeloma Foundation, 2010-present
- Chair, Myeloma Committee, ECOG-ACRIN Cancer Research Group, 2006-present
- Chair, Myeloma, Amyloid, Dysproteineria (MAD) Disease Oriented Group, Mayo Clinic 2006-2016
- Robert A. Kyle Lifetime Achievement Award, International Myeloma Foundation, 2016
- Edward W. and Betty Knight Scripps Professor of Honor of Dr. E. C. Rosenow III, 2015
- Janet Davison Rowley Patient Impact Research Award, 2015
- John Ultmann Lecture and Award, American Society of Clinical Oncology, 2011